Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The ...
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist, on Tuesday. The U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback